Bieganska Ewa A, Kosinski Przemyslaw, Wolski Marek
Department of Pediatric Surgery, Medical University of Warsaw, 02-091 Warsaw, Poland.
Department of Obstetrics, Perinatology and Gynecology, Medical University of Warsaw, 02-091 Warsaw, Poland.
Biomedicines. 2025 Jun 6;13(6):1393. doi: 10.3390/biomedicines13061393.
: The potential therapeutic role of fecal microbiota transplantation (FMT) in various diseases has been thoroughly studied over the last few decades. However, the majority of studies focus on the adult population, therefore, conclusions regarding the application of FMT in the pediatric population are much less clear. This systematic review aims to summarize the research conducted so far on the efficacy and safety of FMT in the pediatric population, assess the quality of the evidence of its effectiveness, and outline the most promising areas for future research. : We performed a systematic literature search from the index date to 8 June 2024 on the Embase, PubMed, and Web of Science databases. One author screened the resulting 121 articles. Eventually, 35 eligible studies that reported FMT use in seven different diseases were identified. : All of the studies assessed FMT as a safe procedure without many serious adverse effects. The best-documented application, which is the only one recommended in official guidelines, is recurrent infection. Other disease entities in which the use of FMT has been studied with good clinical effects are inflammatory bowel disease, allergic colitis, autism, Tourette syndrome, and colonization with multi-drug-resistant organisms. However, it should be noted that the majority of studies are cohort and case-control studies, without randomization, which translates into low evidence quality. In one randomized, controlled trial focusing on the effect of FMT on weight loss in obese individuals, a lack of effect was found. : While FMT and subsequent iterations of gut microbiota-targeted interventions hold promising therapeutic potential for various disease entities in the pediatric population, the current evidence behind this conclusion is of low quality. Based on current studies, these methods appear to be both effective and safe. However, further randomized clinical trials are necessary, especially within the pediatric population, for which such studies remain scarce.
在过去几十年里,粪便微生物群移植(FMT)在各种疾病中的潜在治疗作用已得到充分研究。然而,大多数研究集中在成人人群,因此,关于FMT在儿科人群中的应用结论尚不清楚。本系统综述旨在总结目前关于FMT在儿科人群中的疗效和安全性的研究,评估其有效性证据的质量,并概述未来研究最有前景的领域。
我们在Embase、PubMed和Web of Science数据库上进行了从索引日期到2024年6月8日的系统文献检索。一位作者筛选了由此产生的121篇文章。最终,确定了35项符合条件的研究,这些研究报告了FMT在七种不同疾病中的应用。
所有研究均评估FMT是一种安全的程序,没有许多严重的不良反应。记录最充分的应用,也是官方指南中唯一推荐的应用,是复发性感染。其他研究使用FMT且临床效果良好的疾病实体包括炎症性肠病、过敏性结肠炎、自闭症、抽动秽语综合征以及多重耐药菌定植。然而,应该注意的是,大多数研究是队列研究和病例对照研究,没有随机分组,这导致证据质量较低。在一项关注FMT对肥胖个体体重减轻影响的随机对照试验中,未发现效果。
虽然FMT以及随后针对肠道微生物群的干预措施对儿科人群中的各种疾病实体具有潜在的治疗前景,但这一结论背后的现有证据质量较低。根据目前的研究,这些方法似乎既有效又安全。然而,有必要进行进一步的随机临床试验,特别是在儿科人群中,因为这类研究仍然很少。